ClinicalTrials.gg
Not yet recruitingNCT07777042HOLO-RemoteUpdated Aug 20, 2026

Augmented Reality Aided Remote Access and Technical Support for Complex Ablation Procedures

An interventional study of HoloLens supported catheter ablation and On-site supported catheter ablation in Atrial Fibrillation (AF), sponsored by University of Luebeck. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University of Luebeck · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Atrial Fibrillation by University of Luebeck — 6 open to participants now, 6 under way, none of them phase 3. Atrial Fibrillation · University of Luebeck.

Started
2026
with 2 others
No phase
7 of 12
5 open now
Registered
12th of 12
by date

Among the 12 studies in Atrial Fibrillation by University of Luebeck, this one is one of 3 that started in 2026, is one of 7 with no phase, and was the 12th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 12 studies in Atrial Fibrillation by University of Luebeck are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Atrial Fibrillation by University of Luebeck, or all of them as a file.
02

Study summary

Prospective, randomized, controlled, single-center pilot study evaluating the feasibility and safety of augmented reality-based remote technical support using the Microsoft HoloLens and EnSite™ Connected Care compared with conventional on-site support during 3D electroanatomical mapping-guided electrophysiological procedures. The study also assesses the feasibility of an AI-based algorithm integrated into the Medinbox Link system for automated procedural report generation and detection of protocol deviations from standard clinical practice.

Read the detailed description

Prospective, randomized, controlled, monocentric, pilot study to evaluate the feasibility and safety of remote access and technical support using an augmented reality system (Microsoft HoloLens headset) in association with the EnSite™ Connected Care solution (EnSite™ Connect Remote Support, Abbott and Medinbox system, Medinbox) as compared to the on-site support for three-dimensional (3D) electroanatomical mapping-based electrophysiological (EP) procedures. Moreover, the study will evaluate the feasibility of an artificial intelligence (AI)-based algorithm integrated within the Medinbox Link system (Medinbox) to analyse video and audio recordings obtained during the procedure, with the aim of automatically generating procedural reports and identifying protocol deviations from the standard of care.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • Atrial fibrillation
  • Remote access and technical support
  • Augmented reality
  • 3D electroanatomical mapping
  • Catheter ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age ≥ 18 years
  • Indication for 3D electroanatomical mapping-based catheter ablation for the treatment of AF
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Patient is unable or unwilling to provide
  • Patient is included in another randomised clinical trial
  • Inability to comply with the study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    HoloLens Group

    Patients undergoing 3D electroanatomical mapping-based AF ablation procedures using the EnSite™ X EP System operated remotely by means of the EnSite™ Connected Care solution (EnSite™ Connect Remote Support, Abbott and Medinbox system, Medinbox) and the Microsoft HoloLens (Microsoft).

    Procedure: HoloLens supported catheter ablation

  • Active comparator
    On-site Group

    Patients undergoing 3D electroanatomical mapping-based AF ablation procedures using the EnSite™ X EP System operated by the FTE on site, in the Minimal Invasive Centre (MIC) of the hospital. The HoloLens headset and the EnSite™ Connected Care solution will not be used. The communication between the operator (in the operating room) and the FTE (in the control room) will be established by means of radio-based headphones.

    Procedure: On-site supported catheter ablation

Interventions

  • ProcedureHoloLens supported catheter ablation

    Patients undergoing 3D electroanatomical mapping-based AF ablation procedures using the EnSite™ X EP System operated remotely by means of the EnSite™ Connected Care solution (EnSite™ Connect Remote Support, Abbott and Medinbox system, Medinbox) and the Microsoft HoloLens (Microsoft). The HoloLens headset will be implemented to facilitate the communication between the principal operator and the FTE (working in Home Office). The FTE will not be present on site.

  • ProcedureOn-site supported catheter ablation

    Patients undergoing 3D electroanatomical mapping-based AF ablation procedures using the EnSite™ X EP System operated by the FTE on site, in the Minimal Invasive Centre (MIC) of the hospital. The HoloLens headset and the EnSite™ Connected Care solution will not be used. The communication between the operator (in the operating room) and the FTE (in the control room) will be established by means of radio-based headphones.

06

What researchers measure

Primary outcomes

  1. Feasibility: Number of participants in whom remotely supported 3D electroanatomical mapping-based atrial fibrillation ablation is successfully completed

    Feasibility will be assessed as the number and percentage of participants in whom the planned 3D electroanatomical mapping-guided atrial fibrillation ablation procedure is successfully completed using remote technical support provided through an augmented reality system (Microsoft HoloLens headset) in conjunction with the EnSite™ Connected Care solution (EnSite™ Connect Remote Support, Abbott) and the Medinbox system. Successful completion is defined as completion of the planned mapping and ablation procedure without conversion to on-site technical support because of technical failure of the remote support system.

    Time frame: At the end of the catheter ablation procedure.

Secondary outcomes

  1. Number of participants with periprocedural adverse events

    Periprocedural adverse events occurring during the catheter ablation procedure and throughout the index hospitalization will be recorded.

    Time frame: Periprocedural (from initiation of the catheter ablation procedure until hospital discharge)

  2. Procedural time

    Procedural time

    Time frame: At the end of catheter ablation procedure

  3. Fluoroscopy time

    Total fluoroscopy time (minutes) recorded during the catheter ablation procedure.

    Time frame: End of the catheter ablation procedure

  4. Number of participants with successful completion of the intended catheter ablation procedure (the minimum procedural endpoint is successful pulmonary vein isolation)

    Procedural success will be assessed as successful completion of the intended catheter ablation procedure. A minimum procedural endpoint is successful pulmonary vein isolation (PVI), confirmed by entrance block in all pulmonary veins. Additional ablations may be performed at the operator's discretion based on the patient's clinical characteristics and the planned treatment strategy. When additional ablations are planned or performed, procedural success also requires successful completion of these additional lesion sets according to the predefined procedural objectives.

    Time frame: End of the catheter ablation procedure

  5. Number of participants requiring conversion from remote technical support to on-site technical support

    The number of participants in whom the planned remote technical support could not be maintained and conversion to conventional on-site technical support was required because of technical or procedural reasons (only for interventional group)

    Time frame: End of the catheter ablation procedure

  6. Technical issues

    Technical issues with the remote support system and technical issues with the augmented reality system

    Time frame: At the end of catheter ablation procedure

  7. Estimated carbon dioxide emissions associated with technical support

    Estimated carbon dioxide (CO₂) emissions (kg CO₂ equivalent) associated with travel of field technical engineers to and from the participating study site. Emissions will be calculated from the recorded driving distance using a predefined standardized emission factor. In the remote support group, CO₂ emissions will be calculated based on the estimated distance the field technical engineers would drive if they would have to be on site.

    Time frame: End of the catheter ablation procedure

  8. Operator satisfaction with the procedural workflow assessed using 10-point numeric rating scales

    Operator satisfaction with the procedural workflow will be assessed immediately after completion of the catheter ablation procedure using a 10-point numeric rating scale (NRS), where 0 indicates "not satisfied at all" and 10 indicates "completely satisfied."

    Time frame: End of the catheter ablation procedure

  9. Successful development of an artificial intelligence algorithm for analysis of recorded catheter ablation procedures to assess predefined procedural quality criteria

    Feasibility will be assessed by whether the recorded procedural data from the intervention group are sufficient to develop an artificial intelligence (AI)-based algorithm capable of analyzing predefined procedural quality criteria . The outcome will be reported as successful or unsuccessful algorithm development according to predefined technical performance criteria.

    Time frame: By completion of the AI algorithm development phase, up to 3 months after completion of data collection

  10. Radiation dose

    Total radiation exposure recorded during the catheter ablation procedure, reported as dose area product (DAP, Gy·cm²).

    Time frame: End of the catheter ablation procedure

  11. Number of participants requiring conversion from HoloLens-assisted remote support to conventional remote support

    The number of participants in the intervention group in whom HoloLens-assisted remote technical support could not be maintained and support was continued using conventional remote communication without the Microsoft HoloLens headset because of technical or procedural reasons.

    Time frame: End of the catheter ablation procedure

  12. Driving time of field technical engineers

    Driving time (minutes) required for field technical engineers to travel to and from the participating study site. For participants assigned to the remote support group, driving time will be estimated based on the hypothetical travel time that field technical engineers would have required had conventional on-site technical support been provided.

    Time frame: End of the catheter ablation procedure

  13. Driving distance of field technical engineers

    Driving distance (kilometers) traveled by field technical engineers to and from the participating study site. For participants assigned to the remote support group, driving distance will be estimated based on the hypothetical distance that field technical engineers would have traveled had conventional on-site technical support been provided.

    Time frame: End of the catheter ablation procedure

  14. Field technical engineer satisfaction with the procedural workflow assessed using 10-point numeric rating scales

    Field technical engineer satisfaction with the procedural workflow will be assessed immediately after completion of the catheter ablation procedure using a 10-point numeric rating scale (NRS), where 0 indicates "not satisfied at all" and 10 indicates "completely satisfied."

    Time frame: End of the catheter ablation procedure

  15. Successful development of an artificial intelligence algorithm for analysis of recorded catheter ablation procedures to generate automated procedural reports

    Feasibility will be assessed by whether the recorded procedural data from the intervention group are sufficient to develop an artificial intelligence (AI)-based algorithm capable of generating automated procedural reports. The outcome will be reported as successful or unsuccessful algorithm development according to predefined technical performance criteria.

    Time frame: By completion of the AI algorithm development phase, up to 3 moths after completion of data collection

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Data supporting the study are curated at the Clinical Trial Unit of the Department of Rhythmology, University Hospital Schleswig-Holstein, Lübeck, Germany. These data are not shared openly but are available on reasonable request from the corresponding authors.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Feb 2028, 18 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 18 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 20, 2026
StartEst.
Aug 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777042
Lead sponsor
University of Luebeck
Responsible party
Roland Richard Tilz, MD (Prof. Dr., University of Luebeck) — Principal investigator
First posted
Aug 20, 2026
Start date
Aug 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Roland R Tilz, M.D.
Contact
tilz6@hotmail.de
+49 451 500 44580
Sorin S Popescu, M.D.
Contact
sorin.popescu29@yahoo.ro
+49 451 500 77072
Roland R Tilz, M.D.
principal investigator · University of Lübeck, Department of Rhythmology
Sorin S Popescu, M.D.
principal investigator · University of Lübeck, Department of Rhythmology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion